Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells

키워드

참고문헌 (68)

1. Gordon, R., "Skin cancer: an overview of epidemiology and risk factors", Semin. Oncol. Nurs, 29, pp.160~169 (2013)
2. Lomas, A., "A systematic review of worldwide incidence of nonmelanoma skin cancer", Br. J. Dermatol, 166, pp.1069~1080 (2012)
3. Gray-Schopfer, V., "Melanoma biology and new targeted therapy", Nature, 445, pp.851~857 (2007)
4. Marks, R., "Epidemiology of melanoma", Clin. Exp. Dermatol, 25, pp.459~463 (2000)
5. Whiteman, D. C., "Childhood sun exposure as a risk factor for melanoma : a systematic review of epidemiologic studies", Cancer Causes Control, 12, pp.69~82 (2001)
6. Pollock, P. M., "High frequency of BRAF mutations in nevi", Nat. Genet, 33, pp.19~20 (2003)
7. Siegel, R., "Cancer statistics, 2014", CA Cancer J. Clin, 64, pp.9~29 (2014)
8. Ko, J. M., "A new era: melanoma genetics and therapeutics", J. Pathol, 223, pp.241~250 (2011)
9. Tsao, H., "Genetic interaction between NRAS and BRAF mutations and PTEN", MMAC1 inactivation in melanoma, 2004, pp.122, 337~341
10. Davies, H., "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
11. Curtin, J. A., "Distinct sets of genetic alterations in melanoma", N. Engl. J. Med, 353, pp.2135~2147 (2005)
12. Chapman, P. B., "Improved survival with vemurafenib in melanoma with BRAF V600E mutation", N. Engl. J. Med, 364, pp.2507~2516 (2011)
13. Straussman, R., "Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion", Nature, 487, pp.500~504 (2012)
14. Sosman, J. A., "Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib", N. Engl. J. Med, 366, pp.707~714 (2012)
15. Sullivan, R. J., "Resistance to BRAFtargeted therapy in melanoma", Eur. J. Cancer, 49, pp.1297~1304 (2013)
16. Parry, R. V., "CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms", Mol. Cell. Biol, 25, pp.9543~9553 (2005)
17. Schneider, H., "Reversal of the TCR stop signal by CTLA-4", Science, 313, pp.1972~1975 (2006)
18. Pardoll, D. M., "The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev", Cancer, 12, pp.252~264 (2012)
19. Laurent, S., "The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production", J. Transl. Med, 11, pp.108~ (2013)
20. Ishida, Y., "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J, 11, pp.3887~3895 (1992)
21. Freeman, G. J., "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation", J. Exp. Med, 192, pp.1027~1034 (2000)
22. Keir, M. E., "Tissue expression of PD-L1 mediates peripheral T cell tolerance", J. Exp. Med, 203, pp.883~895 (2006)
23. Chapon, M., "Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes", J. Invest. Dermatol, 131, pp.1300~1307 (2011)
24. Hamid, O., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N. Engl. J. Med, 369, pp.134~144 (2013)
25. Kirkwood, J. M., "Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma", Clin. Cancer Res, 16, pp.1042~1048 (2010)
26. Topalian, S. L., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N. Engl. J. Med, 366, pp.2443~2454 (2012)
27. Kwon, E. D., "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial", Lancet Oncol, 15, pp.700~712 (2014)
28. Teply, B. A., "Identification and management of toxicities from immune checkpoint-blocking drugs", Oncology (Williston. Park), (Suppl 3), pp.30~38 (2014)
29. Rosenberg, S. A., "Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know", Nat. Rev. Clin. Oncol, 8, pp.577~585 (2011)
30. Dudley, M. E., "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens", J. Clin. Oncol, 26, pp.5233~5239 (2008)
31. Heylmann, D., "Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide:implications for the immune response", PLoS One, 8, pp.e83384~ (2013)
32. Suzuki, E., "Gemcitabine selectively eliminates splenic Gr-1+", CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, 2005, pp.11, 6713~6721
33. Phan, G. Q., "Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy", Cancer Control, 20, pp.289~297 (2013)
34. Cormier, J. N., "Comparative analysis of the in vivo expression of tyrosinase, MART-1", Melan-A, and gp100 in metastatic melanoma lesions:implications for immunotherapy, 1998, pp.21, 27~31
35. van der, B. P., "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma", J. Immunol, 178, pp.2617~2621 (2007)
36. Morgan, R. A., "Cancer regression in patients after transfer of genetically engineered lymphocytes", Science, 314, pp.126~129 (2006)
37. Johnson, L. A., "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen", Blood, 114, pp.535~546 (2009)
38. Miller, J. S., "The biology of natural killer cells in cancer, infection, and pregnancy", Exp. Hematol, 29, pp.1157~1168 (2001)
39. Seliger, B., "Different regulation of MHC class I antigen processing components in human tumors", J. Immunotoxicol, 5, pp.361~367 (2008)
40. Seliger, B., "HLA class I antigen abnormalities and immune escape by malignant cells", Semin. Cancer Biol, 12, pp.3~13 (2002)
41. Geller, M. A., "Use of allogeneic NK cells for cancer immunotherapy", Immunotherapy, 3, pp.1445~1459 (2011)
42. Miller, J. S., "Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer", Blood, 105, pp.3051~3057 (2005)
43. Parkhurst, M. R., "Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression", Clin. Cancer Res, 17, pp.6287~6297 (2011)
44. Schmidt-Wolf, G. D., "Activated T cells and cytokine-induced CD3＋CD56＋killer cells", Ann. Hematol, 74, pp.51~56 (1997)
45. Schmidt-Wolf, I. G., "Use of a SCID mouse", human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity, 1991, pp.174, 139~149
46. Franceschetti, M., "Cytokine-induced killer cells are terminally differentiated activated CD8cytotoxic T-EMRA lymphocytes", Exp. Hematol, 37, pp.616~628 (2009)
47. Verneris, M. R., "Studies of ex vivo activated and expanded CD8＋ NK-T cells in humans and mice", J. Clin. Immunol, 22, pp.131~136 (2002)
48. Verneris, M. R., "Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8＋ T cells", Blood, 103, pp.3065~3072 (2004)
49. Pievani, A., "Dual-functional capability of CD3＋CD56＋ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity", Blood, 118, pp.3301~3310 (2011)
50. Alvarnas, J. C., "Expansion of cytotoxic CD3＋ CD56＋ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation", Biol. Blood Marrow Transplant, 7, pp.216~222 (2001)
51. Schmidt-Wolf, I. G., "Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells", Cell. Immunol, 169, pp.85~90 (1996)
52. Zhang, Y. S., "CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402", R, 2005, pp.11, 3339~3345
53. Liu, P., "The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1", DTX in vitro and in vivo, 2009, pp.24, 91~98
54. Zhao, Q., "Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro", J. Exp. Clin. Cancer Res, 29, pp.118~ (2010)
55. Zhu, H. H., "Specific anti-leukemic cell effect mediated by dendritic cells pulsed with chronic myelogenous leukemia lysate antigen in vitro", Zhongguo Shi Yan Xue Ye Xue Za Zhi, 11, pp.278~281 (2003)
56. Zhang, S., "Antitumour activities of cytokine-induced killer cells and dendritic cells in vitro and in vivo", Chin. Med. J. (Engl.), 118, pp.1308~1312 (2005)
57. Wang, F. S., "Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo", World J. Gastroenterol, 8, pp.464~468 (2002)
58. Kornacker, M., "Cytokine-induced killer cells against autologous CLL : direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int. J", Cancer, 119, pp.1377~1382 (2006)
59. Kim, H. M., "Antitumor activity of cytokine-induced killer cells against human lung cancer", Int. Immunopharmacol, 7, pp.1802~1807 (2007)
60. 김환묵, "Inhibition of Human Ovarian Tumor Growth by Cytokine-induced Killer Cells", Archives of Pharmacal Research, 30(11), pp.1464~1470 (2007), 대한약학회
61. 김지성, "Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma", Archives of Pharmacal Research, 37(5), pp.559~566 (2014), 대한약학회
62. Sun, S., "Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines", Cancer Biother. Radiopharm, 20, pp.173~180 (2005)
63. Gammaitoni, L., "Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features", Cancer Res, 19, pp.4347~4358 (2013)
64. Dean, M., "Tumour stem cells and drug resistance", Nat. Rev. Cancer, 5, pp.275~284 (2005)
65. Tailor, N. K., "Effective melanoma inhibition by synthetic pentacyclic triterpenoid 2-(3-phenylprop-2-en-1-ylidene)-22beta-hydroxy-3-oxoolean-12-en-28-oic acid: an in vitro and in vivo study", J. Environ. Pathol. Toxicol. Oncol, 32, pp.59~72 (2013)
66. Schott, S., "Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells", Int. J. Cancer, 131, pp.2165~2174 (2012)
67. Choi, W. K., "New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies", Eur. J. Med. Chem, 46, pp.5754~5762 (2011)
68. Jakel, C. E., "An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells", Expert. Opin. Biol. Ther, 14, pp.905~916 (2014)

관련 논문AI추천